Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Insulet Corporation (PODD)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$165.02+6.56%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
7.72 → 7.72 EPS · FY ending Dec 31, 2027 · 15 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 15 to 15; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for PODD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
No major product recalls or safety issues | A primary condition in Insulet Corporation's published investment case. The stated target is No voluntary medical device corrections or recalls. | Intact | New major product recall or safety correction announced | 0 recalls vs 0 target News highlights revenue growth, buybacks, and product enhancements. No reports of recalls or safety issues found. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a growth-oriented healthcare business with recent financial performance in the top half of its industry. The long-term thesis is intact, but the signal has eased from favorable to mildly favorable, and management execution has been volatile.
The valuation model describes PODD as cheap versus peers, while the expectations gap is negative, suggesting expectations may be ahead of what the model supports. The evidence labels pricing as justified overall, with low fragility because it does not combine expensive valuation, weak execution, and turbulent conditions.
Near term, revenue growth has been strong: revenue rose from $569.0 million in 2025-Q1 to $801.7 million in 2026-Q2, with constant-currency growth of 22.7% in the latest quarter. Management has stayed on track with growth and gross-margin priorities, but a guidance cut, a history of a deep miss, and recent peer misses remain risks; the near-term miss risk is assessed as low.
The multi-year view depends on continued revenue growth and gross margin staying around or above management’s 71% priority. Near term, a guidance cut or further job-market weakening would weigh on the setup, while continued earnings strength and higher guidance from healthcare peers would support sector momentum.
PODD’s recent operating progress supports an intact 1-to-3-year thesis, but volatile execution and elevated risk make follow-through important. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Profit margin is near 17%. |
| Broken |
| Operating margin falls below 16% in FY25 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue grows about 23% in 2026 | Insulet grows revenue about 23% a year. | Broken | YoY revenue growth falls below 22% in FY26 | Revenue growth: 19.21% FY2026-Q3; GAAP. Published target: 22% to 24% YoY growth. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 202619.212799 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Repurchase at least 1.25 million shares | A supporting condition in Insulet Corporation's published investment case. The stated target is >=1.25 million shares repurchased. | Intact | Repurchases drop below 1 million shares in next year | Required source inputs unavailable Cannot calculate Share repurchases from the available matching source inputs. Missing inputs are not treated as zero. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$8.05 → $7.72 · observed estimates
$3.93B → $3.75B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $8.05 | $3,926,753,370 | 22 / 24 |
| 2026-07-25 | $8.05 | $3,935,679,388 | 14 / 19 |
| 2026-07-26 | $8.05 | $3,926,753,370 | 22 / 24 |
| 2026-07-27 | $8.05 | $3,935,679,388 | 14 / 19 |
| 2026-07-28 | $8.05 | $3,935,679,388 | 14 / 19 |
| 2026-07-29 | $8.05 | $3,935,465,670 | 14 / 19 |
| 2026-07-30 | $8.05 | $3,926,905,250 | 23 / 25 |
| 2026-07-31 | $8.05 | $3,926,905,250 | 23 / 25 |
| 2026-08-01 | $8.05 | $3,935,465,670 | 14 / 19 |
| 2026-08-02 | $8.05 | $3,926,905,250 | 23 / 25 |
| 2026-08-03 | $8.05 | $3,926,905,250 | 23 / 25 |
| 2026-08-04 | $8.05 | $3,926,905,250 | 23 / 25 |
| 2026-08-05 | $8.05 | $3,935,465,670 | 14 / 19 |
| 2026-08-06 | $8.05 | $3,935,465,670 | 14 / 19 |
| 2026-08-07 | $7.77 | $3,789,934,851 | 15 / 19 |
| 2026-08-08 | $7.77 | $3,789,934,851 | 15 / 19 |
| 2026-08-09 | $7.77 | $3,789,934,851 | 15 / 19 |
| 2026-08-10 | $7.73 | $3,760,367,730 | 23 / 25 |
| 2026-08-12 | $7.73 | $3,753,649,530 | 23 / 25 |
| 2026-08-13 | $7.73 | $3,753,649,530 | 23 / 25 |
| 2026-08-14 | $7.77 | $3,789,934,851 | 15 / 19 |
| 2026-08-15 | $7.77 | $3,789,934,851 | 15 / 19 |
| 2026-08-16 | $7.77 | $3,789,934,851 | 15 / 19 |
| 2026-08-17 | $7.77 | $3,789,934,851 | 15 / 19 |
| 2026-08-18 | $7.77 | $3,789,934,851 | 15 / 19 |
| 2026-08-19 | $7.77 | $3,789,934,851 | 15 / 19 |
| 2026-08-20 | $7.72 | $3,763,667,354 | 15 / 19 |
| 2026-08-21 | $7.72 | $3,763,667,354 | 15 / 19 |
| 2026-08-22 | $7.72 | $3,763,667,354 | 15 / 19 |
| 2026-08-23 | $7.72 | $3,763,667,354 | 15 / 19 |
| 2026-08-24 | $7.72 | $3,763,667,354 | 15 / 19 |
| 2026-08-25 | $7.72 | $3,763,667,354 | 15 / 19 |
| 2026-08-26 | $7.72 | $3,763,667,354 | 15 / 19 |
| 2026-08-27 | $7.72 | $3,763,667,354 | 15 / 19 |
| 2026-08-28 | $7.72 | $3,763,667,354 | 15 / 19 |
| 2026-08-29 | $7.72 | $3,763,673,700 | 15 / 19 |
| 2026-08-30 | $7.72 | $3,763,673,700 | 15 / 19 |
| 2026-08-31 | $7.72 | $3,763,673,700 | 15 / 19 |
| 2026-09-01 | $7.72 | $3,763,673,700 | 15 / 19 |
| 2026-09-02 | $7.72 | $3,763,673,700 | 15 / 19 |
| 2026-09-03 | $7.71 | $3,763,673,700 | 15 / 19 |
| 2026-09-04 | $7.71 | $3,763,673,700 | 15 / 19 |
| 2026-09-05 | $7.71 | $3,763,673,700 | 15 / 19 |
| 2026-09-06 | $7.71 | $3,763,673,700 | 15 / 19 |
| 2026-09-07 | $7.71 | $3,763,673,700 | 15 / 19 |
| 2026-09-08 | $7.71 | $3,763,673,700 | 15 / 19 |
| 2026-09-09 | $7.71 | $3,763,673,700 | 15 / 19 |
| 2026-09-10 | $7.71 | $3,763,673,700 | 15 / 19 |
| 2026-09-11 | $7.71 | $3,763,698,700 | 15 / 19 |
| 2026-09-12 | $7.71 | $3,756,146,470 | 15 / 19 |
| 2026-09-13 | $7.71 | $3,756,146,470 | 15 / 19 |
| 2026-09-14 | $7.71 | $3,756,146,470 | 15 / 19 |
| 2026-09-15 | $7.71 | $3,756,146,470 | 15 / 19 |
| 2026-09-16 | $7.71 | $3,756,146,470 | 15 / 19 |
| 2026-09-17 | $7.71 | $3,756,146,470 | 15 / 19 |
| 2026-09-18 | $7.71 | $3,756,146,470 | 15 / 19 |
| 2026-09-19 | $7.71 | $3,756,146,470 | 15 / 19 |
| 2026-09-20 | $7.71 | $3,756,146,470 | 15 / 19 |
| 2026-09-21 | $7.71 | $3,756,146,470 | 15 / 19 |
| 2026-09-22 | $7.71 | $3,756,146,470 | 15 / 19 |
| 2026-09-23 | $7.71 | $3,756,146,470 | 15 / 19 |
| 2026-09-24 | $7.71 | $3,756,146,470 | 15 / 19 |
| 2026-09-25 | $7.71 | $3,751,642,122 | 15 / 19 |
| 2026-09-26 | $7.71 | $3,751,642,122 | 15 / 19 |
| 2026-09-27 | $7.71 | $3,751,635,500 | 15 / 19 |
| 2026-09-28 | $7.71 | $3,751,635,500 | 15 / 19 |
| 2026-09-29 | $7.71 | $3,751,635,500 | 15 / 19 |
| 2026-09-30 | $7.71 | $3,751,635,500 | 15 / 19 |
| 2026-10-01 | $7.72 | $3,752,852,892 | 15 / 19 |
| 2026-10-02 | $7.72 | $3,752,852,892 | 15 / 19 |
| 2026-10-03 | $7.72 | $3,752,852,892 | 15 / 19 |
| 2026-10-04 | $7.72 | $3,752,852,892 | 15 / 19 |
| 2026-10-05 | $7.72 | $3,752,852,892 | 15 / 19 |
| 2026-10-06 | $7.71 | $3,750,026,805 | 15 / 19 |
| 2026-10-07 | $7.71 | $3,750,026,805 | 15 / 19 |
| 2026-10-08 | $7.71 | $3,750,026,805 | 15 / 19 |
| 2026-10-09 | $7.71 | $3,750,026,805 | 15 / 19 |
| 2026-10-10 | $7.71 | $3,750,026,805 | 15 / 19 |
| 2026-10-11 | $7.70 | $3,748,083,326 | 15 / 19 |
| 2026-10-12 | $7.70 | $3,748,083,326 | 15 / 19 |
| 2026-10-13 | $7.70 | $3,745,822,457 | 15 / 19 |
| 2026-10-14 | $7.70 | $3,745,822,457 | 15 / 19 |
| 2026-10-15 | $7.70 | $3,745,822,457 | 15 / 19 |
| 2026-10-16 | $7.72 | $3,745,822,457 | 15 / 19 |
| 2026-10-17 | $7.72 | $3,745,822,457 | 15 / 19 |
| 2026-10-18 | $7.72 | $3,745,822,457 | 15 / 19 |
| 2026-10-19 | $7.72 | $3,745,822,457 | 15 / 19 |
| 2026-10-20 | $7.72 | $3,745,822,457 | 15 / 19 |
| 2026-10-21 | $7.72 | $3,745,822,457 | 15 / 19 |
| 2026-10-22 | $7.72 | $3,745,822,457 | 15 / 19 |
| 2026-10-23 | $7.72 | $3,745,822,457 | 15 / 19 |
| 2026-10-24 | $7.72 | $3,745,822,457 | 15 / 19 |
| 2026-10-25 | $7.72 | $3,745,822,457 | 15 / 19 |
| 2026-10-26 | $7.72 | $3,745,822,457 | 15 / 19 |
| 2026-10-27 | $7.72 | $3,745,822,457 | 15 / 19 |
| 2026-10-28 | $7.72 | $3,745,822,457 | 15 / 19 |
| 2026-10-29 | $7.72 | $3,746,819,192 | 15 / 19 |
| 2026-10-30 | $7.72 | $3,746,819,192 | 15 / 19 |
| 2026-10-31 | $7.72 | $3,746,819,192 | 15 / 19 |
| 2026-11-01 | $7.72 | $3,746,819,192 | 15 / 19 |
| 2026-11-02 | $7.72 | $3,746,819,192 | 15 / 19 |
| 2026-11-03 | $7.72 | $3,746,819,192 | 15 / 19 |
| 2026-11-04 | $7.72 | $3,746,819,192 | 15 / 19 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 15 Buy / Strong Buy · 11 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
1 raises · 1 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.